Compare LTRN & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRN | CRIS |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 14.6M |
| IPO Year | 2020 | 2000 |
| Metric | LTRN | CRIS |
|---|---|---|
| Price | $3.60 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $25.00 | $16.50 |
| AVG Volume (30 Days) | 71.4K | ★ 114.9K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $2.55 | $1.02 |
| 52 Week High | $6.12 | $4.50 |
| Indicator | LTRN | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 40.13 |
| Support Level | $3.72 | $1.29 |
| Resistance Level | $3.98 | $1.41 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 48.72 | 23.54 |
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.